Carregant...
LB16. Phase 3 Trial of Baloxavir Marboxil in High-Risk Influenza Patients (CAPSTONE-2 Study)
BACKGROUND: Baloxavir marboxil (BXM), an oral selective cap-dependent endonuclease inhibitor, is effective and safe for treating acute influenza in otherwise healthy patients. METHOD: We conducted an international, randomized, double-blind, placebo (PLC)- and oseltamivir (Os)-controlled treatment st...
Guardat en:
| Publicat a: | Open Forum Infect Dis |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6254082/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy229.2190 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|